{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:31:38Z","timestamp":1782736298472,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41409-018-0360-9","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T15:38:26Z","timestamp":1541777906000},"page":"877-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease"],"prefix":"10.1038","volume":"54","author":[{"given":"Gerald","family":"Wulf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Nickelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Leha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"360_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"360_CR2","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood. 2010;116:3418\u201325.","journal-title":"Blood"},{"key":"360_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/sj.bmt.1704392","volume":"33","author":"KW Zamkoff","year":"2004","unstructured":"Zamkoff KW, Matulis MD, Mehta AC, Beaty MW, Hutchison RE, Gentile TC. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant. 2004;33:635\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"360_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","volume":"27","author":"AK Blystad","year":"2001","unstructured":"Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27:711\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"360_CR5","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F D\u2019Amore","year":"2012","unstructured":"D\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139.","journal-title":"J Clin Oncol"},{"key":"360_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.thj.6200359","volume":"5","author":"P Reimer","year":"2004","unstructured":"Reimer P, Schertlin T, Rudiger T, Geissinger E, Roth S, Kunzmann V, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J. 2004;5:304\u201311.","journal-title":"Hematol J"},{"key":"360_CR7","first-page":"171","volume":"82","author":"F Zaja","year":"1997","unstructured":"Zaja F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L, et al. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica. 1997;82:171\u20137.","journal-title":"Haematologica"},{"key":"360_CR8","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1182\/blood.V80.11.2938.2938","volume":"80","author":"BG Gordon","year":"1992","unstructured":"Gordon BG, Warkentin PI, Weisenburger DD, Vose JM, Sanger WG, Strandjord SE, et al. Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. Blood. 1992;80:2938\u201342.","journal-title":"Blood"},{"key":"360_CR9","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Gouill Le","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26:2264\u201371. e-pub ahead of print 2008\/04\/09","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"360_CR10","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172\u20136.","journal-title":"J Clin Oncol"},{"key":"360_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1046\/j.1365-2141.1999.01666.x","volume":"107","author":"N Dhedin","year":"1999","unstructured":"Dhedin N, Giraudier S, Gaulard P, Esperou H, Ifrah N, Michallet M, et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin\u2019s lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol. 1999;107:154\u201361.","journal-title":"Br J Haematol"},{"key":"360_CR12","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"GS Le","year":"2008","unstructured":"Le GS, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26:2264\u201371.","journal-title":"J Clin Oncol"},{"key":"360_CR13","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","volume":"22","author":"ED Jacobsen","year":"2011","unstructured":"Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome. Ann Oncol. 2011;22:1608\u201313.","journal-title":"Ann Oncol"},{"key":"360_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/sj.bmt.1704600","volume":"34","author":"B Glass","year":"2004","unstructured":"Glass B, Nickelsen M, Dreger P, Claviez A, Hasenkamp J, Wulf G, et al. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplant. 2004;34:391\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"360_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/sj.bmt.1705036","volume":"36","author":"GG Wulf","year":"2005","unstructured":"Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2005;36:271\u20133.","journal-title":"Bone Marrow Transplant"},{"key":"360_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","volume":"15","author":"B Glass","year":"2014","unstructured":"Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15:757\u201366.","journal-title":"Lancet Oncol"},{"key":"360_CR17","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"360_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"360_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333\u20138.","journal-title":"Blood"},{"key":"360_CR20","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970\u20136.","journal-title":"J Clin Oncol"},{"key":"360_CR21","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","volume":"20","author":"M Nickelsen","year":"2009","unstructured":"Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol. 2009;20:1977\u201384.","journal-title":"Ann Oncol"},{"key":"360_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/ajh.24992","volume":"93","author":"JY Zhang","year":"2018","unstructured":"Zhang JY, Briski R, Devata S, Kaminski MS, Phillips TJ, Mayer TL, et al. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol. 2018;93:394\u2013400.","journal-title":"Am J Hematol"},{"key":"360_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3288-7","author":"S Rohlfing","year":"2018","unstructured":"Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Schonland S, Luft T, et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018. \n                    https:\/\/doi.org\/10.1007\/s00277-018-3288-7","journal-title":"Ann Hematol"},{"key":"360_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","volume":"120","author":"KW Song","year":"2003","unstructured":"Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120:978\u201385.","journal-title":"Br J Haematol"},{"key":"360_CR25","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520\u20136.","journal-title":"Leukemia"},{"key":"360_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855\u201364.","journal-title":"Lancet Oncol"},{"key":"360_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrclinonc.2011.51","volume":"8","author":"F Foss","year":"2011","unstructured":"Foss F. Hematology: relapsed and refractory PTCL--into the therapeutic abyss. Nat Rev Clin Oncol. 2011;8:321\u20132.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0360-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:13:17Z","timestamp":1684617197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0360-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0360-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"27 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}